{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-075473","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-09-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.976418+00:00","generated_at":"2026-06-10T22:28:37.337079+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nektar terminates collaboration agreement with Bristol-Myers Squibb for bempegaldesleukin","bullets":["Parties entered letter agreement on Sept 6, 2023 to terminate the 2018 Strategic Collaboration Agreement.","Collaboration covered development of bempegaldesleukin in combination with BMS's Opdivo (nivolumab).","Global clinical development program for the combination was already ended in April 2022.","Termination effective immediately per the letter agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-075473","json":"https://secwatch.observer/filing/0001213900-23-075473.json","markdown":"https://secwatch.observer/filing/0001213900-23-075473.md","text":"https://secwatch.observer/filing/0001213900-23-075473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023075473/0001213900-23-075473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023075473/ea184617-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T22:28:37.337079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1af0ebfa9f4be743ef07b5bebd7ff14d7cfd3757","claim":"NEKTAR THERAPEUTICS terminated Strategic Collaboration Agreement with Bristol-Myers Squibb Company (effective 2023-09-06).","evidence_excerpt":"the parties entered into a letter agreement (the “Letter Agreement”) to terminate the Strategic Collaboration Agreement.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023075473/0001213900-23-075473-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Bristol-Myers Squibb Company"},{"label":"Effective","value":"2023-09-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}